Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 7, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 7.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 7, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 30, 2027 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Trial Milestone | Phase 1 |
| December 30, 2027 | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors | Trial Milestone | Phase 1 |
| April 30, 2028 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Trial Milestone | Phase 3 |
| July 15, 2031 | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) | Trial Milestone | Phase 2 |
Track RLAY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RLAY in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 21, 2026 | 8-K filed: Material agreement | Corporate | — |
| May 19, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 5, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 27, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| March 16, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| February 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 3, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| November 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 7, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 11, 2025 | 8-K filed: Leadership change | Corporate | — |
| June 4, 2025 | 8-K filed: Material agreement | Corporate | — |
| May 5, 2025 | Quarterly results filed (8-K) | Earnings | — |
| March 18, 2025 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.